K-pop

Singer-songwriter Giselle Signs Exclusive Contract with Royal Streamer

New Song "Melancholy" to Be Released on the 20th

KIM HYUNSIK
2026-08-20 19:26:51
[Edaily Starin KIM HYUNSIK Reporter] Singer-songwriter Jiselle has joined the entertainment tech company Royal Streamer.
(Photo courtesy of Royal Streamer)
Royal Streamer announced on the 20th that it had “signed an exclusive contract with Jiselle.”
Since her debut in 2019 with the single “Don’t Answer,” Jiselle has continued her career by collaborating with various artists, including Chancellor, Changmo, and B.I.
Royal Streamer stated, “We plan to utilize Jisell’s artist intellectual property (IP) to present diverse content that combines cutting-edge technologies, such as persona AI chat and extended reality (XR) concerts.”
Giselle marked a fresh start by releasing her new song “Melancholy” that day. “Melancholy” is a track that blends Giselle’s signature sensual vocals with dreamy R&B sounds, featuring rapper Sokodomo.
Royal Streamer stated, “Giselle plans to meet fans through university festival stages and live performances in the U.S.”

Economy

Corporation

IT·Science

Economy

Samsung Electronics Kicks Off '250 Trillion Won Return to Shareholders'… 'Shareholder-Friendly Trend' Spreads Through the Business Community

SamsungElectronics and SK hynix have begun large-scale shareholder returns using cash reserves accumulated during the artificial intelligence (AI) memory boom. According to estimates from the securiti…
2026-08-20 19:00:56

Corporation

SILICON 2 Co.,Ltd., a 'K-Beauty Distributor,' Sets Sights on the Wellness Market… Global Launch of 'Gamtan Bra'

SILICON 2 Co.,Ltd., a K-Beauty distribution platform company, is expanding its business into the wellness sector by introducing the innerwear brand “Gamtan Bra” to the global market. SILICON 2 Co.,Ltd…
2026-08-20 18:39:16

IT·Science

Could a Change in Indications Be a Blessing in Disguise?… What AprilBio Co.,Ltd. Needs to Do for 'APB-A1' to Make a Comeback

AprilBio Co.,Ltd.(397030)Since “APB-A1” (Lu AG22515), which was licensed to Lundbeck, failed to demonstrate the expected clinical efficacy in thyroid-associated ophthalmopathy (TED), the company is no…
2026-08-20 17:32:02